Chemistry:Lifastuzumab vedotin
From HandWiki
Short description: Pharmaceutical drug
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | phosphate-sodium cotransporter |
| Clinical data | |
| Other names | DNIB0600A |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6504H10028N1744O2018S46 |
| Molar mass | 146416.72 g·mol−1 |
Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2]
This drug was developed by Genentech/Roche.
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110". WHO Drug Information 27 (4). https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.
 |  |
